Antibiotic treatment in children with High Risk Febrile Neutropenia Background: In children with cancer and high risk febrile neutropenia (HRFN), the initial empirical treatment used in our hospital for 5 years includes the association of Cloxacillin + Ceftazidime + Amikacin. There is no chilean literature that reviews the effectiveness of this therapy. Objective: Evaluate the clinical and microbiological effectiveness of this associated therapy in children with HRFN. Method: A prospectivedescriptive study evaluating children with HRFN admitted at Hospital Luis Calvo Mackenna between January 2005-August 2006. Results: 100 HRFN episodes were evaluated. In 48% of cases, the antimicrobial treatment was considered effective, whereas in 52% of episodes the therapy required modifications (15% cases within the first 72 hours). The most frequent diagnoses were fever without clinical focus (51%) and sepsis (13%). 36% had microbiological identification and the most frequently isolated bacteria were Escherichia coli (9%) and Staphylococcus aureus (9%). Conclusions: A favorable answer with the initial empirical therapy was obtained for 48% of cases; meanwhile in the remaining episodes, 28% required antibiotics modifications without justification. This fact remarks the importance of following the established guidelines for antimicrobial treatment modification in these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.